Top

Published in:

01-07-2010 | Letter to the Editor

Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence

Authors: Miguel Muñoz, Marisa Rosso, Fernando Casinello, Rafael Coveñas

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Excerpt

Aristotle’s Techné Concept Knowledge and understanding belong to art (techné) rather than to experience, and we suppose artists to be wiser than men of experience; and this because the former know the cause, but the latter do not. For men of experience know that the thing is so, but do not know why, while the others know the ‘why’ and the cause.

(Metaphysics by Aristotle. Book I)

…

Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI (2006) Can anesthetics technique for primary breast cancer surgery affect recurrence of metastases? Anesthesiology 105:660–664CrossRefPubMedPubMedCentral

Kehlet H (1998) Modification of responses to surgery by neural blockade: clinical implications. In: Cousins M, Bridenbough M (eds) Neural blockade in clinical anesthesia and pain management. Lippincott-Raven, Philadelphia, pp 129–175

Ben-Eliyahu S (2002) The price of anticancer intervention. Does surgery promote metastasis? Lancet Oncol 3:578–579PubMed

Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE (2000) The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 90:1411–1414CrossRefPubMed

Yeager MP, Collacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM (1995) Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83:500–508CrossRefPubMed

Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signalling and promotes breast tumor growth. Cancer Res 62:4491–4498PubMed

Muñoz M, Rosso M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17:504–513CrossRefPubMed

Li YM, Wingrov DE, Too HP, Marnerakis M, Stimson ER, Strichartz GR, Maggio JE (1995) Local anesthetics inhibit substance P binding and evoked increases in intracellular Ca2⁺. Anesthesiology 82:166–173CrossRefPubMed

Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231–238CrossRefPubMed

10.

Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (2007) NK-1 receptor antagonists induce apoptosis and counteract substance p-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26:111–118CrossRefPubMed

11.

Khare VK, Albino AP, Reed JA (1998) The neuropeptide/mast cell secretagogue substance P is expressed in cutaneus melanocytic lesions. J Cutan Pathol 25:2–10CrossRefPubMed

12.

Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792CrossRefPubMed

13.

Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:1388–1393

14.

Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732, 138. Invest Ophthalmol Vis Sci 48:2775–2781CrossRefPubMed

15.

Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E (2005) Broad-spectrum G protein-coupled receptor antagonist, [d-Arg1, DTrp5, 7, 9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65:2738–2745CrossRefPubMed

16.

Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F (2009) Neurokinin 1-receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem 284:9280–9289CrossRefPubMedPubMedCentral

17.

Muñoz M, Rosso M (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28:187–193CrossRefPubMed

Title: Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence
Authors: Miguel Muñoz
Marisa Rosso
Fernando Casinello
Rafael Coveñas
Publication date: 01-07-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0850-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2010

Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis

Two founder BRCA2 mutations predispose to breast cancer in young women

Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy

Temporal trends in area socioeconomic disparities in breast-cancer incidence and mortality, 1988–2005

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance

New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer